Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Busulfan (compound)


PubChem
Name: Busulfan
PubChem Compound ID: 2478
Description: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Molecular formula: C6H14O6S2
Molecular weight: 246.304 g/mol
Synonyms:
Sulphabutin; Myelosan; Buzulfan; C.B. 2041; AIDS123905; Tetramethylene bis[methanesulfonate]; CCRIS 418; Leucosulfan; Tetramethylene dimethane sulfonate; Mielevcin.
show more »
DrugBank
Identification
Name: Busulfan
Name (isomeric): DB01008
Drug Type: small molecule
Description: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Synonyms:
Sulfabutin; Busulphan; Sulphabutin; Busulphane; Tetramethylene Dimethane Sulfonate; Butanedioldimethanesulfonate; Buzulfan; Tetramethylenester Kyseliny Methansulfonove
Brand: Mitosan, Myeleukon, Myleran, Misulban, Mylecytan, Myelosan, Myleran Tablets, Mielosan, Mitostan, Busulfex, Mielucin, Myeloleukon, Milecitan, Mablin, Citosulfan, Leucosulfan, Mileran, Mielevcin
Category: Antineoplastic Agents, Myeloablative Agonists, Antineoplastic Agents, Alkylating, Alkylating Agents, Immunosuppressive Agents
CAS number: 55-98-1
Pharmacology
Indication: For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (FDA has designated busulfan as an orphan drug for this use). Also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
Pharmacology:
Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attac...
show more »
Mechanism of Action:
Busulfan is an alkylating agent that contains 2 labile methanesulfonate groups attached to opposite ends of a 4-carbon alkyl chain. Once busulfan is hydrolyzed, the methanesulfonate groups are released and carbonium ions are produced. These carbonium ions alkylate DNA, which results in the interference of DNA replication and RNA transcription, ulti...
show more »
Absorption: Completely absorbed from the gastrointestinal tract.
Protein binding: 32.4%
Biotransformation: Mainly Hepatic. Busulfan is predominantly metabolized by conjugation with glutathione, both spontaneously and by glutathione S-transferase (GST) catalysis.
Route of elimination: Following administration of 14C- labeled busulfan to humans, approximately 30% of the radioactivity was excreted into the urine over 48 hours; negligible amounts were recovered in feces.
Half Life: 2.5 hours
Clearance: 2.52 ml/min/kg [Following an infusion of dose of 0.8 mg/kg every six hours, for a total of 16 doses over four days]
Toxicity: Signs of overdose include allergic reaction, unusual bleeding or bruising, sudden weakness or unusual fatigue, persistent cough, congestion, or shortness of breath; flank, stomach or joint pain; pronounced nausea, vomiting, diarrhea, dizziness, confusion, or darkening of the skin, chills, fever, collapse, and loss of consciousness.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Drink liberally.
Take without regard to meals.
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed.
ThioguanineBusulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy.
TelithromycinTelithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed.
MetronidazoleMetronidazole increases the effect/toxicity of busulfan

Targets


Enzymes